Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for PT Medikaloka Hermina Tbk's 14-Day RSI or its related term are showing as below:
ISX:HEAL's 14-Day RSI is ranked better than 73.86% of 700
companies
in the Healthcare Providers & Services industry
Industry Median: 46.535
vs ISX:HEAL: 38.96
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
PT Medikaloka Hermina Tbk 14-Day RSI Related Terms
ISX:HEAL vs HCA, THC, EHC: 14-Day RSI Comparison
For the Medical Care Facilities subindustry, PT Medikaloka Hermina Tbk's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Medikaloka Hermina Tbk 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Medikaloka Hermina Tbk's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where PT Medikaloka Hermina Tbk's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Medikaloka Hermina Tbk (ISX:HEAL) has a 14-Day RSI of 38.96 as of Sep. 14, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PT Medikaloka Hermina Tbk and its competitors. According to the industry distribution chart, PT Medikaloka Hermina Tbk ranks #183 out of 700 companies in the Healthcare Providers & Services industry, placing it in the top 26.1%.
Is PT Medikaloka Hermina Tbk's 14-Day RSI too high?
PT Medikaloka Hermina Tbk's current 14-Day RSI is 38.96. The Healthcare Providers & Services industry median 14-Day RSI is 46.54. PT Medikaloka Hermina Tbk's value of 38.96 is 16.3% below this industry median. Based on the distribution chart, PT Medikaloka Hermina Tbk ranks #183 out of 700 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PT Medikaloka Hermina Tbk has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Medikaloka Hermina Tbk's 14-Day RSI compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Medikaloka Hermina Tbk ranks #183 out of 700 companies for 14-Day RSI. This puts PT Medikaloka Hermina Tbk in the upper half of its industry. The industry median 14-Day RSI is 46.54. PT Medikaloka Hermina Tbk's value of 38.96 is 16.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 46.54, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Medikaloka Hermina Tbk's current 14-Day RSI of 38.96 is 16.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PT Medikaloka Hermina Tbk and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 46.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Medikaloka Hermina Tbk's current 14-Day RSI is 38.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Medikaloka Hermina Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk (ISX:HEAL) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp1,573.66, compared to a current price of Rp675.00 — trading 57.1% below its estimated fair value. The current 14-Day RSI is 38.96 and 16.3% below the Healthcare Providers & Services industry median of 46.54. PT Medikaloka Hermina Tbk's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For PT Medikaloka Hermina Tbk (ISX:HEAL), the current 14-Day RSI is 38.96 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Medikaloka Hermina Tbk (ISX:HEAL) Overvalued in 2026?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk stock appears to be undervalued.
The current stock price of Rp675.00 is trading 57.1% below its estimated GF Value™ of Rp1,573.66.
GuruFocus considers PT Medikaloka Hermina Tbk to be Significantly Undervalued.
Key valuation signals for ISX:HEAL:
14-Day RSI: 38.96
GF Value™: Rp1,573.66 vs. price of Rp675.00 (57.1% below fair value)
Industry Position: 16.3% below the Healthcare Providers & Services median (#183 of 700)
No single metric tells the full story. See the ISX:HEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Medikaloka Hermina Tbk is a private hospital group. It provides a range of medical services, including maternal and child health services, complex operating procedures, laboratory services, radiology facilities, and fertility treatments as well as general health services, pharmacies, diagnostic and emergency services. The company's geographical segment includes Kalimantan dan Sulawesi, Jawa, and Sumatera. It derives maximum revenue from the Jawa segment.
66GF Score
Get the complete analysis for ISX:HEAL
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:HEAL has been successfully added to your 
